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IntroductIon
One in nine women has a lifetime risk of developing 
breast cancer. With the establishment of breast cancer 
screening programs and patient education about self 
examination breast cancer can be detected and man-
aged in its early stages. Improvements and develop-
ments in the treatment of breast cancer include the use 
of breast conserving therapy and radiotherapy instead 
of radical mastectomy, chemotherapy, monoclonal 
antibodies and hormone therapy. All these tools have 
helped decrease the mortality from breast cancer. As 
more patients are surviving the disease the side effects 
both long term and short term are becoming more and 
more of a concern. Research is focused at understand-
ing the mechanism of action and designing ways of 
improving preventing and monitoring the side effects. 
Cardiac toxicity from radiotherapy, chemotherapy and 
use of monoclonal antibodies has been a concern in 
the treatment of early breast cancer as well as the long 
term effects of use of hormone therapy.
Text
Studies investigating breast conserving treatment as an 
alternative to radical or modified radical mastectomy 
demonstrated equivalent results in the management 
of early breast cancer1. In the early studies however 
it was noted that in patients undergoing breast con-
serving surgery and radiotherapy cardiac toxicity was 
the primary cause of mortality for excess non breast 
cancer mortality1. Radiation to the heart causes both 
acute and chronic symptoms of cardiac toxicity2,3. The 
acute symptoms include acute pericarditis, pericar-
dial effusion and arrhythmias. The long term effects 
are constrictive pericarditis and increased arthroscle-
rosis. The risk is greatest with left breast irradiation 
and radiation involving the internal mammary lymph 
nodes.
Radiation injures the endothelium of coronary ves-
sels leading to ischemic injury to myocytes. Biopsy 
findings from autopsies of patients with heart disease 
who received radiotherapy demonstrate increase fibro-
sis in the pericardium, myocardium and endocardium 
and severe atherosclerosis around the proximal ostia 
of the coronary arteries4. The resultant fibrosis leads 
to diastolic dysfunction.
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Radiation induced cardiac toxicity was more prom-
inent in the earlier studies rather than recent studies. 
This is due to the change in methods and technology 
used to treat breast cancer patients. Older methods of 
breast irradiation involved the treatment of large ar-
eas of breast, chest wall and regional nodes resulting 
in irradiation of large volumes of the heart9. In addi-
tion equipment for treatment and planning lacked the 
sophistication to delineate and avoid irradiation to 
normal tissue structures. The old equipment which in-
volved the use of anterior photon beams and Cobalt 
60 or orthovoltage therapy exposed greater volumes 
of the heart to irradiation. In the 1980s the advent and 
use of tangential fields and megavoltage linear ac-
celerators improved results. In the 1990s CT based 
3D conformal treatment planning which allows for 
the better protection of normal tissue structures was 
introduced. Further developments include the use of 
IMRT and free breathing gating to decrease the risk of 
cardiovascular complications6. In addition the internal 
mammary lymph nodes are not routinely included in 
the treatment field.
Chemotherapy in the adjuvant setting plays an 
important role in breast cancer management and an-
thracyclines and taxanes are central to chemotherapy 
protocols. Cardiovascular complications can be acute 
such as pericarditis, myocarditis, left ventricular 
dysfunction and arrhythmias or long term resulting 
in congestive heart failure and systolic dysfunction. 
Taxanes which are used in combination with anthra-
cyclines potentiate this toxicity by interfering with 
metabolism and excretion. Anthracycline cause type 
one cardiac toxicity this is a dose dependant irrevers-
ible response with characteristic biopsy changes7. The 
mechanism of action is via the induction of oxida-
tive stress resulting in myocyte degeneration which 
is seen in biopsies as myofibrilar loss and vocuolar 
degeneration. Risk factors for anthracycline cardiac 
toxicity include age greater than 70 years of age, high 
blood pressure, preexisting coronary artery disease, 
female sex, previous cardiac irradiation and bolus 
administration8. The minimization of anthracycline 
induced cardiotoxicity can be achieved by infusional 
rather than bolus administration, giving the less toxic 
liposomal forms, opting for epirubicin which is less 
toxic than doxorubicin and limiting maximum dose9. 
There are also some drugs being investigated such as 
Dextrazoxane10,11 which is an iron chelator that mini-
mizes oxidative stress however it has been shown to 
lower response rates to therapy due to stablelisation of 
DNA topoisomerase complexes.
Adjuvant Transtuzumab is given to women posi-
tive for EGFR/Her 2 receptor cardiac toxicity. Cardiac 
toxicity from this drug will present either as symp-
tomatic congestive heart failure or asymptomatic left 
ventricular ejection decline12. Cardiac toxicity from 
Tranztuzumab is classified as type two it is reversible 
and does not produce the ultra structural changes and 
cell death seen with anthracyclines it rather causes a 
type of cell dysfunction, in addition cardiac toxicity 
is not dose dependant7. Instead of myocyte death with 
Transtuzumab there is a change in geometry in con-
tractile proteins which may explain the reversibility 
of this effect4. Stimulation of the Her 2 neu receptor 
can protect against oxidative stress caused by anthra-
cyclines therefore blockage can potentiate anthracy-
cline induced oxidative damage. Risk factors of Tr-
anstuzumab cardiac toxicity include low LVEF prior 
to initiation of Trastuzumab therapy, cumulative dose 
of anthracycline, increased age and prior use of an-
tihypertensive. Exclusion criteria from Tranztuzumab 
include preexisting cardiac disease, prior MI, angina, 
cardiac dysfunction, heart failure, uncontrolled hyper-
tension, and arrhythmia except rate controlled SVT 
and low LVEF prior to treatment. The prevention of 
cardiac toxicity is through close monitoring every 3 
months up to 9 months of treatment with a new as-
sessment 6 months after treatment with ECHO or 
MUGA.
The two forms of hormone therapy which may 
affect the cardiovascular system are Tamoxifen and 
the newer third generation aromatase inhibitors. It is 
well known that estrogens have a protective effect on 
lipid profile therefore the question at hand is whether 
antiestrogens increase the risk of coronary artery dis-
ease13. Tamoxifen has mixed agonist and antagonist 
effect on estrogen receptors and with respect to lipid 
profile it has a positive effect decreasing total cho-
lesterol and LDL cholesterol levels while increasing 
triglycerides2,14. Despite this it has another cardiovas-
cular risk due to the fact that it increases the likeli-
ness of thromboembolic events. Aromatase inhibitors 
are now replacing Tamoxifen as first line therapy in 
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post menopausal women. Studies reviewing the data 
from various trials15,16,17,18,19 show that unlike Tamox-
ifen Aromatase inhibitors don’t improve lipid profiles 
however they don’t make them worse either.
dIScuSSIon
Efforts to understand the underlying mechanisms 
which lead to cardiac toxicity have allowed the de-
velopment of methods of minimizing these effects. In 
the field of radiotherapy these developments are seen 
through the use of conformal therapies, IMRT and 
breathe gating which minimize greatly the amount of 
radiation which is received by organs at risk such as 
the heart. Although the use of Anthracyclines is still 
common in breast cancer treatment the availabil-
ity of liposomal forms the close monitoring of car-
diac function as well as cardio protective drugs have 
helped keep toxicity to a minimum. Close monitoring 
of cardiac function also plays an important role when 
administering Transtuzumab. Studies on the toxicity 
profiles of the new Aromatase inhibitors have proven 
their safety with respect to cardiovascular side effects. 
All these developments have resulted in better safety 
and improved quality of life in breast cancer patients.
concluSIon
Cardiovascular effects of the various breast cancer 
treatments still remain a problem today however the 
more we have come to understand the physiolological 
effects of these methods and with the help of newer 
technologies we can ensure women a good quality of 
life.
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ΠΕΡΙΛΗΨΗ: Σταδιακά περισσότερες γυναίκες επιβιώνουν με νόσο από καρκίνο του μαστού και η ποιότητα ζωής αποτελεί 
επικεντρωμένο στόχο καθώς αυτή (QOL) διαταράσσεται από τις παρενέργειες των θεραπειών.  Για αρκετά χρόνια είναι 
γνωστή η τοξικότητα του καρδιαγγειακού συστήματος από τις θεραπείες (όπως χημειοθεραπεία, ακτινοθεραπεία, ορμονοθε-
ραπεία και στοχευμένη θεραπεία) που αφορούν τον καρκίνο του μαστού.  Καθώς προοδευτικά γνωρίζουμε τους μηχανισμούς 
δράσης των θεραπειών αυτών, μας δίνεται η δυνατότητα να βελτιώσουμε τα θεραπευτικά σχήματα μέσω νέων μεθόδων και 
σκευασμάτων με απώτερο στόχο τον περιορισμό της καρδιοτοξηκότητας των θεραπειών αυτών.
Λέξεις Κλειδιά: Καρκίνος του στήθους, Καρδιακή τοξικότητα, Ακτινοθεραπεία, Χημειοθεραπεία.
Η επίδραση της θεραπείας του πρωίμου καρκίνου  
του μαστού στο καρδιοαγγειακό σύστημα.
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